February 28, 2023 natcopharma-wpdmn No Comments Natco Pharma (Canada) Inc. announces the launch of PrNAT-POMALIDOMIDE Capsules, the first generic alternative to POMALYST® in Canada Read more Read More
September 20, 2022 natcopharma-wpdmn No Comments Natco Canada launches NAT-Apixaban Tablets Read More
January 6, 2022 natcopharma-wpdmn No Comments NATCO completes acquisition of Dash Pharmaceuticals LLC Read more > Read More
December 6, 2021 natcopharma-wpdmn No Comments NATCO receives approval for a drug for the treatment of Covid-19 in India Read more > Read More
December 6, 2021 natcopharma-wpdmn No Comments NATCO proposes to acquire Dash Pharmaceuticals LLC Read more > Read More
November 6, 2021 natcopharma-wpdmn No Comments NATCO launches Tipanat tablets in India, for the treatment of advanced colorectal and gastric cancer Read more > Read More
October 6, 2021 natcopharma-wpdmn No Comments NATCO announces launch of its 10mg strength for Everolimus Tablets (generic for Afinitor®) in the US market Read more > Read More
September 8, 2021 natcopharma-wpdmn No Comments Press Releases Lorem Ipsum is simply dummy text of the printing and typesetting industry. Read More
September 1, 2021 natcopharma-wpdmn No Comments Natco Pharma (Canada) Inc. announces the launch of PrNAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid® Read more > Read More
August 4, 2021 natcopharma-wpdmn No Comments NATCO transfers Lenalidomide ANDA to Arrow Read more > Read More
June 14, 2021 natcopharma-wpdmn No Comments NATCO receives approval for Carfilzomib Vials ANDA (generic for KYPROLIS® ) in the US market Read more > Read More
May 26, 2021 natcopharma-wpdmn No Comments NATCO receives tentative approval for Ibrutinib tablets (generic for IMBRUVICA®) ANDA in the US market Read more > Read More
May 22, 2021 natcopharma-wpdmn No Comments NATCO receives USFDA approval for Lenalidomide Capsules Read more > Read More
May 21, 2021 natcopharma-wpdmn No Comments NATCO starts Phase-III Clinical Trial of Molnupiravir capsules for Covid-19 treatment Read more > Read More
May 17, 2021 natcopharma-wpdmn No Comments NATCO signs Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India Read more > Read More
May 3, 2021 natcopharma-wpdmn No Comments NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment Read more > Read More
April 26, 2021 natcopharma-wpdmn No Comments NATCO seeks Emergency approval of Molnupiravir capsules for Covid-19 treatment Read more > Read More
March 26, 2021 natcopharma-wpdmn No Comments NATCO receives final approval for Everolimus tablets (generic for Afinitor® ) for the US market Read more > Read More
February 26, 2021 natcopharma-wpdmn No Comments NATCO launches Brivaracetam tablets, in India, for treatment of epilepsy Read more > Read More
February 26, 2021 natcopharma-wpdmn No Comments NATCO launches NAT-Bendamustine powder for suspension 25mg and 100mg, in Canada Read More
January 26, 2021 natcopharma-wpdmn No Comments NATCO launches NAT-Abiraterone tablets 250mg, in Canada Read More
January 1, 2021 natcopharma-wpdmn No Comments NATCO receives final approval for Everolimus tablets (generic for ZORTRESS9) in the US market Read more > Read More
